Please ensure Javascript is enabled for purposes of website accessibility

Instant Analysis: Gilead Sciences Inc.'s Longtime CEO Steps Down

By Brian Feroldi - Jan 29, 2016 at 3:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a double dose of bummer news for shareholders today.

What's happening?
Gilead Sciences
 (GILD 0.62%) announced today that longtime CEO John Martin will be moving out of the corner office and taking on the role of executive chairman of the biotech giant. Replacing Martin will be Gilead's current president and COO, John F. Milligan. The transition is scheduled to go into effect on March 10, 2016.

John Cogan, Gilead's lead independent director, summed up Martin's contribution to the company succinctly:

John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear -- and the vision he has set will continue with his contributions as Executive Chairman.

Does it matter?
There's no doubt that shareholders have benefited greatly from Martin's 20-year run at the top. Anyone smart enough to buy shares when he took over as CEO has enjoyed one heck of an impressive run, as shares have gone up by more than 8,000% under his watch.

GILD Chart

Navigating through a leadership change is always challenging, but it looks like Gilead is doing everything correctly to ensure a smooth transition. Martin will still play an active role in shaping the company's future, and the incoming CEO looks like a great choice.

Still, the company picked a rough day to make this announcement. Shares of Gilead were already trading lower on the news that Merck's (MRK 1.10%) new hepatitis C drug Zepatier won Food and Drug Administration approval on Thursday night. While the news of the drug's approval wasn't all that surprising, the announced pricing was a bit shocking. Merck priced Zepatier at $54,600 for a 12-week course, which represents a 42% discount to Gilead's Harvoni. That huge discount could put huge pressure on Gilead to lower its pricing for its hepatitis C treatments, which would weigh heavily on the company's financial statements. After all, Gilead's hepatitis C products comprised more than 58% of its total revenue last quarter, so investors have reason to be nervous. That puts even an even bigger burden on the company to deliver some good news when it reports its fourth-quarter earnings next week.

Farewell, Dr. Martin. This shareholder is sad to see you go.

Brian Feroldi owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$88.37 (1.10%) $0.96
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.47 (0.62%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.